Etomethazene

Etomethazene (5-methyldesnitroetonitazene, 5-methyl etodesnitazene, Eto) is a benzimidazole derivative with opioid effects which has been sold as a designer drug over the internet since early 2022. It is an analogue of etonitazene where the nitro (NO2) group has been replaced by a methyl (CH3) group. While formal studies into its pharmacology have yet to be carried out, it showed far less potency than etonitazene itself. Etomethazene has an analgesic potency around 20 times that of morphine with a relatively short duration of about 120 min.[1][2][3]

Etomethazene
Identifiers
  • 2-[(4-ethoxyphenyl)methyl]-N,N-diethyl-5-methyl-1H-benzimidazole-1-ethanamine
CAS Number
PubChem CID
Chemical and physical data
FormulaC23H31N3O
Molar mass365.521 g·mol−1
3D model (JSmol)
  • CCOc3ccc(Cc2nc1cc(C)ccc1n2CCN(CC)CC)cc3
  • InChI=1S/C23H31N3O/c1-5-25(6-2)14-15-26-22-13-8-18(4)16-21(22)24-23(26)17-19-9-11-20(12-10-19)27-7-3/h8-13,16H,5-7,14-15,17H2,1-4H3
  • Key:ZARKNPABJGEAOQ-UHFFFAOYSA-N

See also

References
  1. "Early signal alert: Emergence of online mentions of etomethazene". National Drug Early Warning System. 1 July 2022.
  2. "5-methyl Etodesnitazene (citrate)". Caymanchem.com.
  3. KLASSIFICERINGSDOKUMENT Narkotika. Etometazen (5-metyletodesnitazen)



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.